These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32146176)

  • 1. Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease.
    Li W; Yang X; Song Q; Cao Z; Shi Y; Deng Y; Zhang L
    Bioorg Chem; 2020 Apr; 97():103707. PubMed ID: 32146176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
    Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
    Bioorg Chem; 2017 Apr; 71():305-314. PubMed ID: 28267984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
    Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
    Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Hydroxy-4-benzyloxylimine Resveratrol Derivatives as Potential Multifunctional Agents for the Treatment of Parkinson's Disease.
    Cao Z; Zhang T; Fu X; Wang X; Xia Q; Zhong L; Zhu J
    ChemMedChem; 2023 Mar; 18(6):e202200629. PubMed ID: 36622947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors.
    Tzvetkov NT; Stammler HG; Neumann B; Hristova S; Antonov L; Gastreich M
    Eur J Med Chem; 2017 Feb; 127():470-492. PubMed ID: 28107736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
    Nam MH; Park M; Park H; Kim Y; Yoon S; Sawant VS; Choi JW; Park JH; Park KD; Min SJ; Lee CJ; Choo H
    ACS Chem Neurosci; 2017 Jul; 8(7):1519-1529. PubMed ID: 28332824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents.
    Matos MJ; Herrera Ibatá DM; Uriarte E; Viña D
    ChemMedChem; 2020 Mar; 15(6):532-538. PubMed ID: 32037726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
    Rodríguez-Enríquez F; Costas-Lago MC; Besada P; Alonso-Pena M; Torres-Terán I; Viña D; Fontenla JÁ; Sturlese M; Moro S; Quezada E; Terán C
    Bioorg Chem; 2020 Nov; 104():104203. PubMed ID: 32932120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: Synthesis, biochemistry, and molecular dynamics study.
    Thomas Parambi DG; Oh JM; Kumar S; Sudevan ST; Hendawy OM; Abdelgawad MA; Musa A; Al-Sanea MM; Ahmad I; Patel H; Kim H; Mathew B
    Comput Biol Chem; 2023 Aug; 105():107899. PubMed ID: 37315342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
    Liu L; Chen Y; Zeng RF; Liu Y; Xie SS; Lan JS; Ding Y; Yang YT; Yang J; Zhang T
    Bioorg Chem; 2021 Apr; 109():104685. PubMed ID: 33640631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
    Agrawal N; Mishra P
    Comput Biol Chem; 2019 Apr; 79():63-72. PubMed ID: 30731360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
    Wang Z; Wu J; Yang X; Cai P; Liu Q; Wang KDG; Kong L; Wang X
    Bioorg Med Chem; 2016 Nov; 24(22):5929-5940. PubMed ID: 27692996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Design, Synthesis of Hybrid Combinations: Quercetin Based MAO Inhibitors with Antioxidant Potential.
    Dhiman P; Malik N; Khatkar A
    Curr Top Med Chem; 2019; 19(2):156-170. PubMed ID: 30747068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
    Tao D; Wang Y; Bao XQ; Yang BB; Gao F; Wang L; Zhang D; Li L
    Eur J Med Chem; 2019 Jul; 173():203-212. PubMed ID: 31005056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors.
    Sasidharan R; Manju SL; Uçar G; Baysal I; Mathew B
    Arch Pharm (Weinheim); 2016 Aug; 349(8):627-37. PubMed ID: 27373997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and analysis of MAO-B inhibitors for Parkinson's disease: using in silico approaches.
    Kare P; Bhat J; Sobhia ME
    Mol Divers; 2013 Feb; 17(1):111-22. PubMed ID: 23325357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
    Dhiman P; Malik N; Khatkar A
    Curr Top Med Chem; 2018; 18(21):1857-1871. PubMed ID: 30430943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
    Yeon SK; Choi JW; Park JH; Lee YR; Kim HJ; Shin SJ; Jang BK; Kim S; Bahn YS; Han G; Lee YS; Pae AN; Park KD
    Bioorg Med Chem; 2018 Jan; 26(1):232-244. PubMed ID: 29198609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.